Based on the mechanism of each component, the patients most likely to benefit from exploring KLOW with their physician are those who: Are actively on a GLP-1 receptor agonist (semaglutide, tirzepatide, retatrutide) and losing weight at a rate of 12+ lb/week Are experiencing visible skin laxity, facial volume loss, or skin texture changes as weight declines Have significant GI side effects (nausea, diarrhoea, mucosal discomfort) during dose escalation Carry known markers of systemic inflammation elevated hsCRP, elevated fasting insulin, or other metabolic biomarkers that have been flagged in prior lab work Are in their 40s or older, where baseline collagen decline makes the gap between demand and capacity most acute Have a history of inflammatory bowel conditions, slow wound healing, or joint/soft tissue injuries that have not fully resolved KLOW is less likely to be the primary tool for patients who are early in GLP-1 therapy, losing weight slowly, have no skin or GI symptoms, and carry no background inflammatory burden
Today, Doctors Best continue to uphold their founders belief that by trusting in science, good health will follow
Can GLPs replace diet and exercise
We need more clinical trials examining the cardiac benefits of SGLT2 inhibitors and GLP-1 agonists for patients prescribed insulin, but with more information on diabetes control and the extent of that benefit provided as the diabetes control is worse. For more information: Joanna Khatib, MBBS , can be reached at [email protected].
To our knowledge, we are one of the few groups working on defining how weight-loss drugs directly impact the function of innate and adaptive immune cells
/assets/images/provider/photos/2805921.jpeg)
